Related Experiment Video

Updated: Oct 13, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.5K

Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter,

Jingen Li1, Zhuye Gao2, Lijing Zhang3

  • 1Department of Cardiology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China; Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Complementary Therapies in Medicine
|November 30, 2019
PubMed

Insights

Adding Qing-Xin-Jie-Yu Granule (QXJYG) to standard therapy reduced cardiovascular events in stable coronary artery disease (SCAD) patients. This traditional Chinese medicine may offer further protection against heart attack and stroke.

Area of Science:

  • Cardiology
  • Traditional Chinese Medicine
  • Pharmacology

Background:

  • Patients with stable coronary artery disease (SCAD) face ongoing cardiovascular event risk despite optimal secondary prevention.
  • Traditional Chinese Medicine (TCM) offers potential complementary therapies for cardiovascular disease management.

Purpose of the Study:

  • To evaluate the efficacy of Qing-Xin-Jie-Yu Granule (QXJYG), a TCM prescription, as an adjunct to standard therapy for reducing cardiovascular events in SCAD patients.
  • To assess the impact of QXJYG on a composite endpoint including cardiovascular death, nonfatal myocardial infarction (MI), and coronary revascularization.

Main Methods:

  • A multicenter, double-blinded, randomized trial involving 1500 SCAD patients.
  • Patients were assigned to receive either QXJYG or a placebo for 6 months, with a subsequent 6-month follow-up period.
  • Primary outcome: composite of cardiovascular death, nonfatal MI, and coronary revascularization. Secondary analysis included a composite of cardiovascular death, nonfatal MI, and ischemic stroke.

Main Results:

  • No significant difference was observed for the primary composite outcome between the QXJYG and placebo groups (1.59% vs. 1.62%).
  • However, the addition of QXJYG significantly reduced the risk of the composite 'hard' endpoint (cardiovascular death, nonfatal MI, ischemic stroke) by 0.99% (0.31% vs. 1.30%).
  • Adverse event rates were comparable between the QXJYG and placebo groups.

Conclusions:

  • The addition of Qing-Xin-Jie-Yu Granule (QXJYG) to standard therapy demonstrated a significant reduction in the risk of nonfatal myocardial infarction and a composite endpoint including cardiovascular death, nonfatal MI, and stroke in SCAD patients.
  • QXJYG may represent a valuable complementary treatment for improving cardiovascular outcomes in patients with stable coronary artery disease.
Abstract

Keywords:
Cardiovascular eventsChinese herbal medicineQing-Xin-Jie-Yu GranuleRandomized controlled trialStable coronary artery disease

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

605

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...